Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04292080
Other study ID # P170919
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 7, 2022
Est. completion date October 2026

Study information

Verified date August 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Eric SOUIED, PU-PH
Phone +33 1 45 17 59 08
Email eric.souied@chicreteil.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).


Description:

Age-related Macular Degeneration (AMD) is the leading cause of irreversible blindness in the industrialized world. Approximately 80% of patients with AMD suffer from the dry form of the disease also called geographic atrophy (GA) which is characterized by the progressive loss of photoreceptors and RPE that are essential to the visual cycle. There is currently no therapy to cure GA. This represent a major health problem with millions patients worldwide. GA is a complex multifactorial disease influenced by: aging, environmental factors, genetic predispositions, oxidative stress and inflammation. Oxidative stress is the major environmental risk factor of developing AMD. Whereas inflammation, is now, recognized as one of the main player in AMD pathophysiology. Therefore, antioxidant and immunosuppressive therapies are susceptible to be beneficial in humans for patients with GA. Dimethyl Fumarate activates the NRF2 pathway, which is the major transcription factor regulating anti-oxidative enzymes production. Dimethyl Fumarate commercialized under the name TECFIDERA® by BIOGEN is an effective antioxidant and immunosuppressive drug, used to treat patients with Multiple Sclerosis (MS), an autoimmune disease of the Central Nervous System leading to progressive disability. This new therapeutic agent may be easily repurposed to treat GA patients and could reduce or slow photoreceptors and RPE degeneration and the associated vision loss. In this randomized, open labelled trial we will evaluate the safety and efficacy of TECFIDERA®, in two groups of patients (treated vs. untreated) with GA. This is the first time this strategy, based on evidences that oxidative stress and inflammation are central in GA physiopathology, will be tested in patients with dry AMD.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 2026
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: Age 55 years of age to 85 years old at the moment of inclusion - Participant must understand and sign the protocol's informed consent document - Participant must have central or non-central geographic atrophy (GA) in at least one eye. GA should be at least 0.75 disk areas (DA) in size but no more than 8 disk areas (DA); approximately 2.54 mm2 is 1 DA. (GA is defined as one or more well-defined, usually more or less circular patches of partial or complete de-pigmentation of the retinal pigment epithelium (RPE), typically with exposure of underlying choroïdal blood vessels. Even if much of the RPE appears to be preserved and large choroïdal vessels are not visible, a round patch of RPE partial de-pigmentation may still be classified as early GA. If a patient has 2 eligible eyes; one eye will be the "study eye", graded and evaluated during the whole duration of the study) - Participant must have a steady fixation in the study eye in the foveal or parafoveal area and media clear enough for good quality photographs - Participant must have visual acuity between 25/25 and 20/200 in the affected eye - No suggestive sign of progressive multifocal leukoencephalopathy on brain MR Imaging within 3 months of Tecfidera© treatment Initiation (Only the patients randomized in the TECFIDERA Group will have to go through the MR Imaging) - Male participants with female partners capable of conceiving children will be required to use contraception (condom) during the study and for four months after their last experimental treatment caps - No documented history of heart disease, absence of family history of sudden death, and QTc duration within normal value (<480ms) - Participants must be affiliated to a social security scheme Exclusion Criteria: - Participant is in another interventional investigational study < 3 months before inclusion - Participant is unable to comply with study procedures or follow-up visits - Participant has evidence of ocular disease other than GA in either eye that may confound the outcome of the study (e.g., glaucoma, diabetic retinopathy with 10 or more hemorrhages or micro-aneurysms, uveitis, pseudo-vitelliform macular degeneration, exudative macular degeneration, moderate/severe myopia) - Participant with antecedent of neo-vascular AMD. - Participant has received treatment for exudative AMD, such as macular laser, photodynamic therapy (PDT) or anti-vascular endothelial growth factor (anti-VEGF) therapy intra-vitreal (IVT) injection or of any agent (e.g., triamcinolone) in the study eye within the last four months prior to study enrollment. Vitamin supplementation for AMD is not considered an exclusionary criterion - Participant has had a vitrectomy - Participant is expected to need ocular surgery during the course of the trial - Participant has undergone lens removal in the last three months or Yttrium Aluminium Garnet (YAG) laser capsulotomy within the last month - Participant is on chemotherapy - Participant is on chronic (more than 3 months) immunosuppressive medication administered via ocular or systemic route(s) or is immunosuppressed - Participant is on ocular or systemic medications known to be toxic to the lens, retina or optic nerve - Participant with a history of malignancy that would compromise the 2-year study survival - Participant with a history of ocular herpes simplex virus (HSV) - Contra-indications or known hyper-sensibility to Dimethyl Fumarate (Tecfidera™) or experimental treatment excipients - Severe active gastrointestinal disease - Contra-indications to an MRI using gadolinium such as pace maker, cardiac valve non IRM compatible, cochlear implant or any metallic implant non IRM compatible. - Any contraindications to gadolinium including pregnancy, previous allergic reaction, severe kidney disease - Any contraindications to aspirin - Any screening laboratory value (hematology, serum chemistry or urinalysis) 3 times above normal values or that in the opinion of the Investigator is clinically significant and not suitable for study participation - Lymphopenia below normal laboratory values at inclusion. - Severe impairment of a vital organ including severe liver and renal impairment - Previous organ allograft - Patients taking the following non-authorized treatment 3 months prior enrolment: other fumaric acid derivatives (topical occular or systemic), immuno-modulators via ocular or systemic routes (including interferons, sirolimus, chronic use of glucocorticoids) cytotoxic treatments and live attenuated vaccines.(NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized treatment cited above is not allowed in patients randomized in the TEFIDERA group). - Patients taking the following non-authorized treatment 3 months prior enrolment: nephrotoxic treatment (aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs (via ocular or systemic routes) or lithium). (NB: During the experimental treatment period and 3 months thereafter the concomitant use of non-authorized nephrotoxic treatment cited above is not allowed in patients randomized in the TEFIDERA group). - Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control) - History of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years that could be worsened by immunosuppression (In case of history of cancer the risk of immunosuppression must be determined by a specific oncology consultation prior to enrollment.) - Ocular or peri-ocular inflammation or infection in either eye - Presence of active or inactive toxoplasmosis in any or both eye(s) - Presence of active or latent tuberculosis infection. - History of depression or of suicidal ideations or HAD score at baseline equal or above 8 For Anxiety (A) or equal or above 8 for Depression D. - Female participants of child bearing potential (those who are not post-menopausal or surgically sterile). Postmenopausal state is 12 months of amenorrhea + high level of FSH if required. - Persons under curatorship or guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dimethyl Fumarate (TECFIDERA™)
Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
Other:
No active : no treatment
30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.

Locations

Country Name City State
France Centre intercommunal de Créteil Créteil Val De Marne

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Month 12 in total area of GA Lesion(s) in the study eye (in mm2) as Measured by Fundus Autofluorescence (FAF) 12 Months
Secondary Incidence and severity of ocular and systemic treatment-related adverse events as assessed by CTCAE v4.0". 24 months
See also
  Status Clinical Trial Phase
Completed NCT01694680 - Intervention Trial in Early Age-related Macular Degeneration N/A
Completed NCT01224847 - Intravitreal Injection Anesthesia - Comparison of Different Topical Agents N/A
Withdrawn NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) Phase 3
Completed NCT05037396 - Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
Completed NCT00647439 - Genetics and Markers of Degenerative and Inflammatory Eye Diseases
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT03690505 - Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place N/A
Recruiting NCT03577041 - Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Completed NCT05082415 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
Completed NCT02445313 - Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
Recruiting NCT00354445 - A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Phase 4
Completed NCT05111743 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Terminated NCT02398500 - Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT05110209 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Completed NCT05146687 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Not yet recruiting NCT05780931 - Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02022540 - Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Phase 1
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A